Browsing Tag
Inluriyo
3 posts
Eli Lilly’s Inluriyo and Verzenio combo data reshape outlook for ER+, HER2– metastatic breast cancer treatment
Eli Lilly’s EMBER-3 update boosts Inluriyo’s profile in breast cancer care—find out how its all-oral combo with Verzenio could shift treatment standards.
FDA approval of Eli Lilly’s Inluriyo: Can the new oral SERD reshape advanced breast cancer treatment?
FDA clears Eli Lilly’s Inluriyo for ESR1-mutated advanced breast cancer. Explore trial data, stock sentiment, pricing, and future oncology outlook.
Eli Lilly wins FDA approval for Inluriyo in ESR1-mutated metastatic breast cancer
FDA approves Eli Lilly’s Inluriyo for ESR1-mutated breast cancer, boosting oncology pipeline and investor confidence. Learn how this reshapes treatment.